Search results for "THERAPY"

showing 10 items of 12482 documents

2018

The catabolic process of autophagy plays important functions in inflammatory and immune responses by modulating innate immunity and adaptive immunity. Over the last decade, a cell-intrinsic role for autophagy in modulating CD4 T cell functions and differentiation was revealed. After the initial observation of autophagosomes in effector CD4 T cells, further work has shown that not only autophagy levels are modulated in CD4 T cells in response to environmental signals but also that autophagy critically affects the biology of these cells. Mouse models of autophagy deletion in CD4 T cells have indeed shown that autophagy is essential for CD4 T cell survival and homeostasis in peripheral lymphoi…

0301 basic medicineInnate immune systemmedicine.medical_treatmentT cellImmunologyCellAutophagyImmunotherapyBiologyAcquired immune systemT-Cell Receptor Activation3. Good healthCell biology03 medical and health sciences030104 developmental biologymedicine.anatomical_structureImmune systemmedicineImmunology and AllergyFrontiers in Immunology
researchProduct

Interleukin-2 Functionalized Nanocapsules for T Cell-Based Immunotherapy.

2016

A major demand on immunotherapy is the direct interference with specific immune cells in vivo. In contrast to antibody-engineered nanoparticles to control dendritic cells function, targeting of T cells for biomedical applications still remains an obstacle as they disclose reduced endocytic activities. Here, by coupling the cytokine interleukin-2 (IL-2) to the surface of hydroxyethyl starch nanocapsules, we demonstrated a direct and specifc T cell targeting in vitro and in vivo by IL-2 receptor-mediated internalization. For this purpose, defined amounts of azide-functionalized IL-2 were linked to alkyne-functionalized hydroxyethyl starch nanocapsules via copper-free click reactions. In combi…

0301 basic medicineInterleukin 2Materials sciencemedicine.medical_treatmentT cellmedia_common.quotation_subjectGeneral Physics and Astronomy02 engineering and technologyNanocapsules03 medical and health sciencesImmune systemIn vivomedicineGeneral Materials ScienceInternalizationmedia_commonGeneral EngineeringImmunotherapy021001 nanoscience & nanotechnologyCell biology030104 developmental biologyCytokinemedicine.anatomical_structureImmunology0210 nano-technologymedicine.drug
researchProduct

Targeted Activation of T Cells with IL-2-Coupled Nanoparticles

2020

Interleukin-2 (IL-2) is a T cell growth factor particularly required in regulatory T cell maintenance and memory T cell responses. High-dose IL-2 treatment was the first FDA-approved immunotherapy for cancer, while low-dose IL-2 administration has shown promise in allograft rejection and autoimmune and inflammatory diseases. However, its pleiotropic nature and the existence of IL-2 receptors with different binding affinity limit its therapeutic application. For an improved clinical applicability of the cytokine, a targeted receptor assignment must, therefore, be achieved. Nanoparticles allow controlling the location and dose of immunomodulating compounds and to specifically address specific…

0301 basic medicineInterleukin 2Regulatory T cellT-Lymphocytesmedicine.medical_treatmentT cellReviewmedicine.disease_causeAutoimmunity03 medical and health sciences0302 clinical medicinemedicineHumansReceptorlcsh:QH301-705.5General MedicineImmunotherapy030104 developmental biologymedicine.anatomical_structureCytokinelcsh:Biology (General)030220 oncology & carcinogenesisCancer researchinterleukin-2nanoparticlesimmunotherapyMemory T cellmedicine.drugCells
researchProduct

The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes

2018

Background Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients. Objective We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. Method After literature search, the available evidence has bee…

0301 basic medicineInterleukin-1betaInflammationAnakinra; Cardiovascular risk; Diabetes; IL-1β; Pathogenesis; Rheumatoid arthritis; Therapy; PharmacologyType 2 diabetesPathogenesisDiabeteProinflammatory cytokinePathogenesisArthritis Rheumatoid03 medical and health sciencesImmune systemPathogenesiDiabetes mellitusmedicineHumansRheumatoid arthritisRheumatoid arthritiPharmacologyAnakinrabusiness.industryDiabetesAntirheumatic AgentReceptors Interleukin-1General Medicinemedicine.diseaseCardiovascular riskSettore MED/16 - Reumatologia030104 developmental biologyAnakinraDiabetes Mellitus Type 2IL-1βRheumatoid arthritisAntirheumatic AgentsImmunologyTherapymedicine.symptombusinessmedicine.drugHuman
researchProduct

The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model.

2021

Abstract STUDY QUESTION Does LH protect mouse oocytes and female fertility from alkylating chemotherapy? SUMMARY ANSWER LH treatment before and during chemotherapy prevents detrimental effects on follicles and reproductive lifespan. WHAT IS KNOWN ALREADY Chemotherapies can damage the ovary, resulting in premature ovarian failure and reduced fertility in cancer survivors. LH was recently suggested to protect prepubertal mouse follicles from chemotoxic effects of cisplatin treatment. STUDY DESIGN, SIZE, DURATION This experimental study investigated LH effects on primordial follicles exposed to chemotherapy. Seven-week-old CD-1 female mice were randomly allocated to four experimental groups: C…

0301 basic medicineLHAlkylating Agentsfertility preservationmedia_common.quotation_subjectDNA repair LH cancer chemotherapy fertility preservation follicle protection ovoprotectionDNA repairOvaryMice SCIDBiologychemotherapyAndrology03 medical and health sciencesMice0302 clinical medicineOvarian FollicleMice Inbred NODPregnancyFollicular phasemedicineAnimalsHumanscancerFertility preservationOvarian follicleOvarian reserveOvarian ReserveOvulationmedia_commonReproductive Biology030219 obstetrics & reproductive medicineRehabilitationObstetrics and GynecologyOriginal ArticlesOocytemedicine.diseaseAcademicSubjects/MED00905Premature ovarian failure030104 developmental biologymedicine.anatomical_structureReproductive Medicinefollicle protectionovoprotectionlipids (amino acids peptides and proteins)FemaleHuman reproduction (Oxford, England)
researchProduct

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening

2018

Graphical abstract

0301 basic medicineLK Polo-like kinasePolo-like kinaseCell cycleIC50 50% inhibition concentrationVirtual drug screeningPLK103 medical and health sciences0302 clinical medicineNeoplasmsTargeted chemotherapylcsh:Science (General)MitosisComputingMethodologies_COMPUTERGRAPHICSCDK cyclin-dependent kinasePBD Polo-box domainPyRxNatural productslcsh:R5-920MultidisciplinaryMicroscale thermophoresisKinaseChemistryCell cycleCell biology030104 developmental biology030220 oncology & carcinogenesisCancer cellOriginal ArticleCAMKK2 calcium/calmodulin-dependent protein kinase kinase 2PC Polo-box caplcsh:Medicine (General)Multipolar spindleslcsh:Q1-390Journal of Advanced Research
researchProduct

Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran

2018

Cutaneous leishmaniasis (CL) is a serious health challenge at the global level due to Leishmania tropica. This study was conducted to evaluate the risk factors associated with anthroponotic CL (ACL) in unresponsive (patient who does not heal and remains with an active lesion, despite receiving two courses of intra-lesional Glucantime along with cryotherapy and one cycle of systemic Glucantime) and responsive patients in a major focus in southeastern Iran. A case-control study was conducted from April 2015 to October 2016 in the southeast of Iran. Patients were recruited in a major ACL focus from unresponsive and responsive cases. These patients were compared for environmental, clinical, and…

0301 basic medicineLeishmania tropicamedicine.medical_treatmentSocial Scienceslcsh:MedicineScarsCryotherapyIranPathology and Laboratory MedicineLogistic regressionPolymerase Chain ReactionGeographical Locations0302 clinical medicineRisk FactorsZoonosesMedicine and Health Scienceslcsh:ScienceLeishmaniasisProtozoansLeishmaniaMultidisciplinaryGeographybiologyEukaryotaInfectious Diseasesmedicine.symptomResearch ArticleNeglected Tropical Diseasesmedicine.medical_specialtyAsiaPatients030106 microbiology030231 tropical medicineLeishmaniasis CutaneousHuman GeographyLesion03 medical and health sciencesSigns and SymptomsCutaneous leishmaniasisDiagnostic MedicineInternal medicineParasitic DiseasesmedicineHumansProtozoan Infectionsbusiness.industrylcsh:ROrganismsHealth Risk AnalysisBiology and Life SciencesOdds ratioDNA ProtozoanTropical Diseasesmedicine.diseasebiology.organism_classificationParasitic ProtozoansConfidence intervalHealth CareAge GroupsLeishmania tropicaCase-Control StudiesPeople and PlacesLesionsEarth SciencesHousingPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Good's syndrome and recurrent leishmaniasis: A case report and review of literature

2020

We report the case of a 56-year-old Caucasian male affected by thymoma and myasthenia gravis that developed recurrent visceral leishmaniasis 11 years after thymectomy. After treatment of each relapse with liposomal amphotericin B the PCR-Leishmania was negative and the patient showed clinical improvement. An immunologic work-up was performed showing lymphopenia with an important decrease in CD4+ T cells (52 cells/μ) and CD4/CD8 ratio (0.2). HIV test was negative. On the basis of previous thymoma and myasthenia gravis and on the basis of the immunological profile a diagnosis of Good's syndrome was made. Since IFNγ plays a main role in the control of Leishmania infection the production of IFN…

0301 basic medicineLeishmaniasiThymomamedicine.medical_treatmentT cellImmunologyLiposomal amphotericin BCase ReportGood's syndromeCD4+ T cell03 medical and health sciences0302 clinical medicinemedicineIntensive care medicinelcsh:Social sciences (General)lcsh:Science (General)LeishmaniasisInternal medicineInfectious diseaseMultidisciplinarybusiness.industryLeishmaniasisImmunotherapymedicine.diseaseLaboratory medicineCD4+ T cellsMyasthenia gravisThymectomy030104 developmental biologyVisceral leishmaniasismedicine.anatomical_structureImmunologylcsh:H1-99business030217 neurology & neurosurgeryCD8IFNγlcsh:Q1-390Heliyon
researchProduct

Medicinal Plants and Natural Products as Potential Sources for Antiparkinson Drugs

2016

Parkinsonʼs disease is a progressive neurodegenerative dysfunction characterized by the loss of pigmented dopaminergic neurons of the nigrostriatal system with a consequent dopamine decrease. The reduction of dopamine levels produces neuronal damage, depigmentation of the substantia nigra, and the presence of intracellular inclusions in dopaminergic neurons. Treatments for Parkinsonʼs disease aim for improving these motor symptoms by increasing the dopaminergic signal in the striatum with levodopa in combination with enzyme inhibitors or anticholinergic drugs. Nevertheless, natural products can act as neuroprotective agents by reducing the progression of the disease and the inflammatory pro…

0301 basic medicineLevodopaPharmaceutical ScienceSubstantia nigraPharmacologyBiologyNeuroprotectionAnalytical ChemistryAntiparkinson Agents03 medical and health sciences0302 clinical medicineDopamineDrug DiscoverymedicineAnimalsHumansPharmacologyBiological ProductsPlants MedicinalPlant ExtractsOrganic ChemistryDopaminergicAntiparkinsonian AgentAntiparkinson drug030104 developmental biologynervous systemComplementary and alternative medicineAntiparkinson AgentsMolecular Medicine030217 neurology & neurosurgeryPhytotherapymedicine.drugPlanta Medica
researchProduct

Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients.

2018

Abstract Eighty percent of hepatocellular carcinoma (HCC) cases occur after cirrhosis from various etiologies. The association between diet and cancer is well accepted, but the links with cirrhosis progression and HCC risk have been poorly investigated. However, we hypothesized that diet could be a modifiable preventive factor for HCC. Thus, the aim of our study was to explore the relationships between dietary factors and the risk of HCC in a population of cirrhotic patients. A total of 582 cirrhotic patients were studied: 401 without HCC (controls) and 181 with HCC (cases). These patients were recruited between 2008 and 2012 for the “CiRCE” case-control study conducted in six French univer…

0301 basic medicineLiver CirrhosisMale*Diet/adverse effectsCirrhosisEndocrinology Diabetes and MetabolismGastroenterologyFood groupchemistry.chemical_compound0302 clinical medicineEndocrinologyDiet and cancerRisk FactorsOdds RatioProspective StudiesProspective cohort study*Case-control studyeducation.field_of_studyNutrition and DieteticsLiver NeoplasmsMiddle Aged3. Good healthHepatocellular carcinomaFemale*Feeding Behavior*Hepatocellular carcinomaFranceLiver Neoplasms/etiology/*prevention and controlVitaminmedicine.medical_specialtyCarcinoma Hepatocellular*CirrhosisPopulation030209 endocrinology & metabolism*Diet03 medical and health sciencesHepatocellular/etiology/*prevention and controlInternal medicinemedicineDiabetes MellitusHumanseducationLiver Cirrhosis/complications/*diet therapyAged030109 nutrition & dieteticsbusiness.industryCarcinomaCase-control studyFeeding Behaviormedicine.diseaseDietLogistic ModelschemistryCase-Control StudiesbusinessEnergy Intake[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyNutrition research (New York, N.Y.)
researchProduct